PSVT prevalence is estimated by contemporary studies at 1.26M patients, with an annualized incidence of 189,000. The average PSVT sufferer experiences 3–5 episodes per year, though the deviation ...
“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...
"We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,” said Joseph Oliveto, President and Chief Executive Officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback